Use the hyperlinks, where available to access additional clinical trial information.
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy
Participants in this trial will be randomized into one of two cohorts. In the experimental cohort, participants will receive Varlitinib (300mg, oral tablets twice daily) and Capecitabine (1000mg/m2, oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles) until disease progression, toxicity, withdrawal of consent or death. In the comparator group, participants will receive Capecitabine (as above) and a placebo (oral tablet, twice daily) until disease progression, unacceptable toxicity, withdrawal of consent or death.